MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.96 CHF | +12.45% |
|
+59.15% | +73.26% |
| Jun. 14 | Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... |  |
| Jun. 14 | Wholesale Prices Tick Down in May as US Equity Futures Point to Premarket Losses | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
2024-08-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.96
CHF
Average target price
9.35
CHF
Spread / Average Target
+56.88%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +73.26% | 222M | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| +5.07% | 22.94B | |
| -12.75% | 22.22B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| -39.94% | 16.87B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- US Court Dismisses Putative Class Action Against Molecular Partners
